The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma
Crossref DOI link: https://doi.org/10.1007/s00280-019-03804-7
Published Online: 2019-03-04
Published Print: 2019-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Albin, Nicolas http://orcid.org/0000-0003-0466-0068
Monard, Adrien
Lapiere, Jérémy
Text and Data Mining valid from 2019-03-04
Article History
Received: 20 December 2018
Accepted: 22 February 2019
First Online: 4 March 2019
Compliance with ethical standards
:
: The authors declare that they have no conflict of interests.